secwatch.observer — SEC 8-K summary
======================================

Issuer:     ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK:        0001281895
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001140361-26-008853
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rocket Pharma enters $100M ATM equity facility with Cantor Fitzgerald
---------------------------------------------------------------------

- Agreement with Cantor Fitzgerald to sell up to $100M of common stock via at-the-market offerings.
- Prior ATM agreement with Cowen/ TD Securities terminated upon signing new agreement.
- Sales occur on Nasdaq; Cantor receives up to 3% commission on gross proceeds.
- Shelf registration on Form S-3 filed March 2, 2026, declared effective March 10, 2026.
- Company may suspend or terminate offerings at any time; no obligation to sell.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126008853/0001140361-26-008853-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1281895/000114036126008853/ef20067503_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-008853

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer